For a better user experience please update your browser or use Chrome or Firefox browser.
Uslužni programi
Publication detail
HomeFuture-proofing pharmaceutical legislation
Study on medicine shortages : executive summary
Metapodaci o publikaciji
Member States and many stakeholders, including pharmacy organisations, have signalled a rise in shortages of medicinal products in the European Union (EU). Shortages present a major problem for the quality and continuity of patient care. At best, patients can be provided with an equivalent medicine, but if no such equivalent is available, pharmacists may have to resort to therapeutic substitution. This can increase the risk of reduced treatment compliance or incorrect use of the medicine, leading to lower treatment effectiveness and disease progression. Substitutes may also pose an increased risk or incidence of adverse events. In the worst case, there may be no suitable alternatives. Medicine shortages also have important economic consequences. Many pharmacists spend several hours per week on conferring with prescribers about suitable alternatives and on sourcing these. Patients may face higher costs when prescribed alternatives are more expensive or if they must pay for additional visits with their healthcare provider to discuss alternatives.
- Objavljeno:
- Teme: Farmaceutska i kozmetička industrija
- Predmet: bolest , Europska unija , Europski ekonomski prostor , farmaceutska industrija , medicinski proizvod , nestašica , propisi o lijekovima , veterinarski proizvod
|
PDF
|
|||
| ISSN | ISBN 978-92-76-43524-2 | DOI 10.2875/236176 | Kataloški broj EW-01-21-417-EN-N |
- Released on EU publications website:
Preglednik dokumenata
Note:
Publikacija se ne može prikazati u pregledniku dokumenata. Otvori internetsku verziju
Dostupno na: Preuzmi i odaberi jezik